Strides Pharma Science growth over the years

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Compounded a year	1 yr	3 yr
Revenue	+6.4%	+9.6%
EBITDA	+15.3%	+29.1%
Net Income	−84.1%	—
EPS (adj.)	−84.5%	—
Total Assets	+14.5%	+1.4%
Total Equity	+21.8%	+13.2%
Free Cash Flow	−36.7%	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

STAR₹1,097.50

Strides Pharma Science Ltd.

· Pharma & Health

₹ CrorePeersSPARC SUPRIYA SHILPAMED THYROCARE RUBICON VIYASH YATHARTH PARKHOSPSMcap ₹10,116 Cr

Annuals · FY-end closes

Compounded Growth Annuals · CAGR %	1Y CAGR	3Y CAGR
Revenue	+6.4	+9.6
EBITDA	+15.3	+29.1
Net Income	-84.1	—
EPS (adj.)	-84.5	—
Total Assets	+14.5	+1.4
Total Equity	+21.8	+13.2
Free Cash Flow	-36.7	—

CAGR from filed annuals — needs positive start & end values.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.